Innovative regenerative medicines in the EU: a better future in evidence?
Name:
BMCart%3A10.1186%2Fs12916-017- ...
Size:
856.9Kb
Format:
PDF
Description:
Full text, Open Access Article
Affiliation
Centre for Reviews and Dissemination, University of York, Heslington, York, YO10 5DDIssue Date
2017-03-08
Metadata
Show full item recordAbstract
Despite a steady stream of headlines suggesting they will transform the future of healthcare, high-tech regenerative medicines have, to date, been quite inaccessible to patients, with only eight having been granted an EU marketing licence in the last 7 years. Here, we outline some of the historical reasons for this paucity of licensed innovative regenerative medicines. We discuss the challenges to be overcome to expedite the development of this complex and rapidly changing area of medicine, together with possible reasons to be more optimistic for the future.Citation
Innovative regenerative medicines in the EU: a better future in evidence? 2017, 15(1):49 BMC MedJournal
BMC MedicineDOI
10.1186/s12916-017-0818-4PubMed ID
28270209Type
ArticleLanguage
enISSN
1741-7015ae974a485f413a2113503eed53cd6c53
10.1186/s12916-017-0818-4
Scopus Count
Collections
Related articles
- The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal.
- Authors: Hettle R, Corbett M, Hinde S, Hodgson R, Jones-Diette J, Woolacott N, Palmer S
- Issue date: 2017 Feb
- Uncertain Oversight of Regenerative Medicines in Japan under the ASRM.
- Authors: Lysaght T, Sugii S
- Issue date: 2016 Apr 7
- Translating cell-based regenerative medicines from research to successful products: challenges and solutions.
- Authors: Bayon Y, Vertès AA, Ronfard V, Egloff M, Snykers S, Salinas GF, Thomas R, Girling A, Lilford R, Clermont G, Kemp P
- Issue date: 2014 Aug
- Regenerative medicine: looking backward 10 years further on.
- Authors: Kemp P
- Issue date: 2016 Dec